Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.
|Number of pages||1|
|Journal||American Journal of Respiratory and Critical Care Medicine|
|Early online date||19 May 2021|
|Publication status||Published - 2021|
|Event||ATS International Conference Committee: ATS 2021 - Virtual event |
Duration: 14 May 2021 → 19 May 2021